Ahold Delhaize USA Renews Emphasis on Data-Driven Growth Supported by Advanced Analytics Tools from Circana
Ahold Delhaize USA Renews Emphasis on Data-Driven Growth
SALISBURY, N.C., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ahold Delhaize USA has reaffirmed its commitment to data-driven growth by renewing its strategic partnership with Circana, LLC. This renewal strengthens the collaboration between the leading grocery retail group and Circana, ensuring continued access to advanced analytic tools that drive innovation and foster deeper collaboration with consumer packaged goods (CPG) companies.
'This renewed focus underscores Ahold Delhaize USA's dedication to staying ahead in a competitive and ever-evolving retail landscape by using data as a strategic advantage to create value for all stakeholders,' said Keith Nicks, chief digital officer, Ahold Delhaize USA. 'Circana's platform enables Ahold Delhaize USA companies to provide both CPG partners and internal teams with the tools and insights needed to make data-driven decisions.'
Circana is the preferred data provider for Ahold Delhaize USA companies, supplying analytical support to strengthen decision-making, improve supply chain efficiencies and better understand shopper behaviors. In 2025, the partnership will introduce new enhancements to further this work, including:
A unified common product hierarchy (CPH): Ensuring consistency and precision in data analysis.
Enhanced reporting: Simplifying collaboration with streamlined insights.
A comprehensive performance view: Offering a holistic perspective across all Ahold Delhaize USA brands.
Innovative tools: Resources like a weekly shopper promotional evaluation tool and supply chain forecast for more accurate demand planning and promotional effectiveness.
'We are thrilled to extend our strategic partnership with Ahold Delhaize USA,' said Rob Hill, president of global retail at Circana. 'We look forward to continuing to support Ahold Delhaize USA's local brands in delivering value to their shoppers and partners.'
About Ahold Delhaize USA Ahold Delhaize USA, a division of global food retailer Ahold Delhaize, is part of the U.S. family of brands, which also includes five leading omnichannel grocery brands: Food Lion, The GIANT Company, Giant Food, Hannaford and Stop & Shop. When considered together, the companies of Ahold Delhaize USA comprise the largest grocery retail group on the East Coast and the fourth largest in the nation, serving millions of omnichannel customers each week. For more information, visit www.adusa.com.
About Circana Circana is a leading advisor on the complexity of consumer behavior. Through superior technology, advanced analytics, cross-industry data, and deep expertise, we provide clarity that helps almost 7,000 of the world's leading brands and retailers take action and unlock business growth. We understand more about the complete consumer, the complete store, and the complete wallet so our clients can go beyond the data to apply insights, ignite innovation, meet consumer demand, and outpace the competition. Learn more at circana.com.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/376d8537-0db4-4d0a-b6cd-ece9cc706010
CONTACT: MEDIA CONTACT mediarelations@adusa.comSign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
3 hours ago
- Business Upturn
Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
Long-term efficacy and safety data on PALSONIFY TM (paltusotine) in acromegaly to be presented, including evidence of both biochemical and symptom control with a well-tolerated safety profile in patients switching treatments and those not previously pharmacologically treated Atumelnant Phase 2 trial results in congenital adrenal hyperplasia (CAH) to be featured in oral presentation Data from early-stage development program in Graves' hyperthyroidism and orbitopathy also to be featured SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced eight abstracts from its novel clinical development programs, including oral presentations featuring its lead investigational drug candidate, PALSONIFY™ (paltusotine)* and investigational candidate atumelnant, will be presented at the Endocrine Society's Annual Meeting, ENDO 2025, July 12-15, 2025, in San Francisco, California. 'ENDO 2025 will be an incredibly meaningful moment for Crinetics in our mission to be the premier endocrine-focused global pharmaceutical company,' said Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics. 'For our lead investigational candidate PALSONIFY for acromegaly, we are excited to present long-term data that continue to support the durable, consistent response profile it has shown in earlier pivotal trials. Additionally, compelling Phase 2 trial results from atumelnant in CAH and new data from one of our early-stage development programs demonstrate that the Crinetics pipeline can address significant unmet needs.' Four abstracts will report results from the PALSONIFY development program, including an oral presentation featuring open-label extension data from the registrational Phase 3 PATHFNDR trials. This presentation will highlight long-term efficacy, safety, and symptom control in people with acromegaly who switched from injectable somatostatin receptor ligands (SRLs) to once-daily oral PALSONIFY. In addition, Crinetics will present three poster presentations: one evaluating symptom stability in acromegaly, one analyzing patient-reported outcomes from both PATHFNDR-1 and PATHFNDR-2 and another on PATHFNDR-2 open-label extension data. Together, these abstracts show PALSONIFY continues to be well tolerated, while providing consistent biochemical and symptomatic disease control. Crinetics will also present three abstracts from its atumelnant clinical development program, including an oral presentation of Phase 2 trial results in congenital adrenal hyperplasia (CAH). Additional presentations focus on reduction of adrenal volume and rapid and sustained reductions in potent 11-oxygenated androgens, a novel biomarker, in Phase 2 trial participants. Beyond its two lead programs, Crinetics will present new data from its early-stage pipeline, including data from CRN12755 for Graves' hyperthyroidism and orbitopathy. Additional presentation details are shown below. All times are PT: *The U.S. Food and Drug Administration recently conditionally approved PALSONIFY as the trade name for paltusotine, our once-daily, oral investigational candidate for acromegaly. PALSONIFY™ (paltusotine) Presentations Title: Paltusotine Results in Improved Symptom Stability in Biochemically Controlled Acromegaly Authors: David Clemmons, MD et. al. Date/Time: July 13, 12:00-1:30 PM Location: Session P34 – Neuroendocrinology and Pituitary: Acromegaly, Prolactinoma, Other Functioning Pituitary Tumors (Except Cushing) II – ENDOExpo Poster Area: SUN-043 Title: Effects of Paltusotine Treatment on Patient-Reported Symptoms of Acromegaly in Phase 3 Randomized Placebo-Controlled Studies (PATHFNDR-2 and PATHFNDR-1) Authors: Avery A. Rizio, PhD et. al. Date/Time: July 13, 12:00-1:30 PM Location: Session P34 – Neuroendocrinology and Pituitary: Acromegaly, Prolactinoma, Other Functioning Pituitary Tumors (Except Cushing) II – ENDOExpo Poster Area: SUN-052 Title: Disease Control in Patients With Acromegaly Switching From Injected Somatostatin Receptor Ligands to Once-Daily Oral Paltusotine: Interim Results of the PATHFNDR-1 Open-Label Extension Authors: Beverly M. K. Biller, MD et. al. Date/Time: July 13, 2:45-3:00 PM Location: Session OR12-07 – Neuroendocrinology and Pituitary: Management of Pituitary Disorders – Room 201 Title: Once-Daily Oral Paltusotine in the Treatment of Patients With Biochemically Uncontrolled Acromegaly: Interim Results of the PATHFNDR-2 Open-Label Extension Authors: Monica R. Gadelha, MD, PhD et. al. Date/Time: July 14, 12:00–1:30 PM Location: Session P77 – Neuroendocrinology and Pituitary: Acromegaly, Prolactinoma, Other Functioning Pituitary Tumors (except Cushing) III – ENDOExpo: Poster Area; MON-069 Atumelnant Presentations Title: Reductions in Adrenal Volume in Patients With Congenital Adrenal Hyperplasia Receiving Once-Daily Oral Atumelnant (CRN04894): Interim Results From a 12-Week, Phase 2, Open-Label Study Authors: Tania A.S.S. Bachega, MD, PhD et. al. Date/Time: July 12, 12:15-1:45 PM Location: Session P18 – Adrenal (Excluding Mineralocorticoids): Adrenal Insufficiency and CAH I – ENDOExpo Poster Area: SAT-452 Title: Once-Daily Oral Atumelnant (CRN04894) Induces Rapid, Substantial, and Sustained Reductions of Androstenedione and 17‑Hydroxyprogesterone in Adults With Classical Congenital Adrenal Hyperplasia: Interim Results From a 12-Week, Phase 2, Open-Label Study Authors: Umasuthan Srirangalingam, MD, PhD et. al. Date/Time: July 12, 2:30-2:45 PM Location: Session OR07-06 – Adrenal (Excluding Mineralocorticoids): All About Congenital Adrenal Hyperplasia and Adrenal Insufficiency – Room 204 Title: -Rapid and Sustained Reduction of 11-Oxygenated Androgens in Adults With Classic Congenital Adrenal Hyperplasia Following Once-Daily Oral Atumelnant (CRN04894): Results From a 12-Week, Phase 2, Open-Label Study Authors: Nicole Reisch, MD et. al. Date/Time: July 13, 12:00-1:30 PM Location: Session P55 – Adrenal (Excluding Mineralocorticoids): Adrenal Insufficiency and CAH II – ENDOExpo Poster Area: SUN-438 Early-Stage Pipeline Presentations Title: Discovery and Characterization of an Orally Bioavailable Nonpeptide Thyroid Stimulating Hormone Receptor (TSHR) Antagonist for the Treatment of Graves' Disease and Thyroid Eye Disease Authors: Eulalia A. Coutinho, PhD et. al. Date/Time: July 14, 12:00-1:30 PM Location: Session P92 – Thyroid Biology and Disease: Benign Thyroid Disorders (Auto-Immune) II – ENDOExpo Poster Area: MON-365 Crinetics Sponsored Science & Innovation Theaters Title: Optimizing Long-Term Control in Acromegaly: Key to Improved Patient Outcomes Presenters: Shlomo Melmed, MB ChB; Christian J. Strasburger, MD Date/Time: July 14, 9:30 AM-10:30 AM Location: Theater 1 Title: Navigating the Complexities & Challenges of Acromegaly Management Presenters: Lisa B. Nachtigall, MD; Laurence Katznelson, MD; Scott Struthers, PhD Date/Time: July 14, 12:30 PM -1:30 PM Location: Theater 1 About PALSONIFY™ (Paltusotine) Crinetics' lead development candidate, PALSONIFY, is the first investigational once-daily, oral, selectively-targeted somatostatin receptor type 2 (SST2) nonpeptide agonist that has completed Phase 3 clinical development for acromegaly and is in Phase 3 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It was designed to be a once-daily oral option for the control of acromegaly and carcinoid syndrome. In Phase 3 studies, once-daily, oral PALSONIFY maintained IGF-1 levels and symptom control in patients with acromegaly who were switched from monthly injectable medications (PATHFNDR-1) and rapidly decreased IGF-1 levels and symptom burden in medically untreated acromegaly patients (PATHFNDR-2). IGF-1 is the primary biomarker endocrinologists use to manage acromegaly patients. Results from a Phase 2 study in carcinoid syndrome demonstrated rapid and sustained reductions in flushing episodes and bowel movement frequency, which are the most common symptoms of carcinoid syndrome, leading to the initiation of a Phase 3 trial for control of carcinoid syndrome in patients with neuroendocrine tumors. About Atumelnant Atumelnant, Crinetics' second investigational compound, is the first once-daily, oral adrenocorticotropic hormone (ACTH) receptor antagonist that acts selectively at the melanocortin type 2 receptor (MC2R) on the adrenal gland. Diseases associated with excess ACTH can have significant impact on physical and mental health. Atumelnant has exhibited strong binding affinity for MC2R in preclinical models and has demonstrated suppression of adrenally derived glucocorticoids and androgens that are under the control of ACTH. Data from a 12-week Phase 2 study demonstrated compelling treatment benefits of atumelnant, evidenced by the rapid, substantial and sustained statistically significant reductions in key CAH disease related biomarkers, including androstenedione and 17-hydroxyprogesterone, in a diverse population. Atumelnant is in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, with the Phase 3 CALM-CAH trial and a Phase 1/2b trial in ADCS currently enrolling patients. About Crinetics Pharmaceuticals Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics' lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome. All of the company's drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the plans and timelines for the clinical development of atumelnant and paltusotine, including the therapeutic potential and clinical benefits or safety profile thereof; the plans and timelines for the commercial launch PALSONIFY if approved; the potential clinical benefits of our TSHR antagonist, CRN12755, in patients across multiple indications, and the anticipated timing of clinical trials, registration applications or the therapeutic potential for our development candidates. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplates,' 'believes,' 'estimates,' 'predicts,' 'potential,' 'upcoming' or 'continue' or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including, without limitation, initial or topline data that we report may change following completion or a more comprehensive review of the data related to the clinical studies and such data may not accurately reflect the complete results of a clinical study, and the FDA and other regulatory authorities may not agree with our interpretation of such results; geopolitical events may disrupt Crinetics' business and that of the third parties on which it depends, including delaying or otherwise disrupting its clinical studies and preclinical studies, manufacturing and supply chain, or impairing employee productivity; the success of Crinetics' clinical studies and nonclinical studies; regulatory developments in the United States and foreign countries; clinical studies and preclinical studies may not proceed at the time or in the manner expected, or at all; the timing and outcome of research, development and regulatory review is uncertain, and Crinetics' drug candidates may not advance in development or be approved for marketing; and the other risks and uncertainties described in the Company's periodic filings with the Securities and Exchange Commission (SEC). The events and circumstances reflected in the company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found under the heading 'Risk Factors' in Crinetics' periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2024 and quarterly report on Form 10-Q for the quarter ended March 31, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Crinetics does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact: Media: Natalie Badillo Head of Corporate Communications [email protected] (858) 345-6075
Business Upturn
3 hours ago
- Business Upturn
Shoals Technologies Group, Inc. Announces Battery Energy Storage Systems ('BESS') Webinar
By GlobeNewswire Published on July 1, 2025, 02:30 IST PORTLAND, Tenn., June 30, 2025 (GLOBE NEWSWIRE) — Shoals Technologies Group, Inc. ('Shoals' or the 'Company') (Nasdaq: SHLS), a global leader in electrical balance of systems ('EBOS') solutions for the energy transition market, announced today that it has released a webinar on the subject of Battery Energy Storage Systems ('BESS'), followed by Q&A. The webinar is intended to be educational and informative. Further, it is being provided to allow customers, investors, analysts and other interested parties to learn more about the BESS market landscape, Shoals' BESS solutions, Shoals' paths to market, strategy and competitive position. No financial projections are implied or intended. Featured speakers include Mike Everson, BESS Account Executive, Matt Tractenberg, VP of Finance & Investor Relations, and Lindsey Williams, VP of Marketing & Communications. You can access the recorded webinar, along with the accompanying presentation, through the Investor Relations section of the Company's website at About Shoals Technologies Group, Inc. Shoals Technologies Group is a leading provider of electrical balance of systems ('EBOS') solutions for the energy transition market. Since its founding in 1996, the Company has introduced innovative technologies and systems solutions that allow its customers to substantially increase installation efficiency and safety while improving system performance and reliability. Shoals Technologies Group is a recognized leader in the renewable energy industry. For additional information, please visit: Contacts: Investor Relations: Matt Tractenberg, VP of Finance and Investor Relations Email: [email protected] Media: Lindsey Williams, VP of Marketing and Communications Email: [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
3 hours ago
- Business Upturn
PetVivo Reports Fiscal 2025 Results
By GlobeNewswire Published on July 1, 2025, 01:10 IST MINNEAPOLIS, MN, US, June 30, 2025 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. and its wholly-owned subsidiary PetVivo Animal Health, Inc. (OTCQB: PETV; OTCPINK: PETVW), a leading biomedical company delivering innovative medical therapeutics for equines and companion animals, reported results for its fiscal year ended March 31, 2025. All comparisons are to the previous fiscal year period unless otherwise noted. The company has filed for an extension for the filing of its Form 10-K for the fiscal year ending March 31, 2025, therefore all financial results reported in this press release are unaudited preliminary estimates, and are subject to change. The company will hold a conference call today at 5:00 p.m. Eastern time to discuss the preliminary results for the year (see dial-in information below). Fiscal 2025 Financial Highlights Revenues increased 17% to a record $1.1 million, with the strong growth due to the company continued expansion from the equine market into the larger and faster-growing companion animal market with sales of the company's lead animal osteoarthritis medical device, Spryng ® with OsteoCushion ™ Technology. with OsteoCushion Technology. National distributor network sales increased 31% to $958,000 or 85% of total revenues, largely driven by the addition of two national distributors. Gross profit increased 15% to $995,000, with gross margin at 87.8%. Operating loss decreased 24% to $8.1 million. The substantial improvement was due to the company's strategic corporate restructuring and cost reduction program implemented during the year, which was partly offset by increased investment in R&D as well as in personnel to support the expansion of the sales and marketing teams to better address the equine and companion animal markets. Net loss decreased 27% to $8 million or $(0.39) per basic and diluted. Net cash used in operating activities decreased by 40% or $2.9 million compared fiscal 2024, primarily due to the strategic company-wide cost reduction and restructuring program. Cash and cash equivalents totaled $227,689 at March 31, 2025, compared to $87,403 at March 31, 2024, with the increase primarily due to equity financings. Subsequent to the fiscal year end, the company raised additional net proceeds of $4.4 million to support its growth strategies for fiscal 2026. As a result, the company's cash and cash equivalents totaled approximately $3.3 million as of June 30, 2025. Fiscal 2025 Operational Highlights Reached major milestone of Spryng ® administered by more than 1,000 veterinary clinics across all 50 states since its official introduction to the veterinary market in 2021, with this having a meaningful impact on the health, well-being and mobility of thousands of equines and companion animals. administered by more than 1,000 veterinary clinics across all 50 states since its official introduction to the veterinary market in 2021, with this having a meaningful impact on the health, well-being and mobility of thousands of equines and companion animals. Entered transformative strategic alliance with Digital Landia, Inc., a pioneer in Agentic artificial intelligence (AI) solutions. Collaboration centers on equine and companion animal AI, Digital Landia's revolutionary technology that deciphers animal behavior and communication through real-time analysis of vocalizations, body language, and physiological signals captured via smartphone cameras with 97% accuracy. This AI-powered technology is being integrated with PetVivo's veterinary products as a first-of-kind global pet care ecosystem, with initial beta testing currently underway. Signed an exclusive licensing and supply agreement with VetStem, Inc. that provides PetVivo the rights to commercialize VetStem's proprietary and revolutionary allogeneic platelet rich plasma (PRP) product, PrecisePRP ® , for horses and dogs. The company has just begun sales of PrecisePRP and is receiving a favorable response from veterinarians regarding the ease of use of this regenerative product. , for horses and dogs. The company has just begun sales of PrecisePRP and is receiving a favorable response from veterinarians regarding the ease of use of this regenerative product. Strengthened our sales and marketing program with the promotion of April Boyce to the new position of vice president of sales and marketing. She has brought to PetVivo more than 25 years of experience in marketing, sales, strategic partnerships, and global product licensing, including executive positions at Procter & Gamble (P&G) and Clorox. Enhanced the commercialization team with the appointment Bryan Monninger as vice president of distributor relations and corporate accounts. He brings to PetVivo more than 20 years of experience in sales and marketing, including senior executive positions at Hill's Pet Nutrition, Novus International and Lintbells, as well as the Fortune 500 companies, Colgate-Palmolive, ConAgra and Hormel Foods. Appointed board certified veterinary surgeon, Dr. Kirsty Husby, DVM, MS, DACVS (LA), to the position of senior technical services veterinarian. She brings to PetVivo more than a decade of experience and accomplishment in animal health, including clinical practice and research experience at leading animal clinics and educational institutions. Dr. Juli Goldstein, DVM, CHPV was appointed to the position of technical services veterinarian, bringing to the role extensive experience across various disciplines, including small animal emergency and general practice, marine wildlife medicine, clinical research, and laboratory animal care in North America and internationally. Teamed with Orthobiologic Innovations, Inc., a leader in R&D for regenerative and sports medicine, to pursue new clinical trials, product development and marketing of Spryng ® . This has resulted in a substantial accumulation of valuable data regarding the application of Spryng ® in a canine elbow osteoarthritis study currently underway. . This has resulted in a substantial accumulation of valuable data regarding the application of Spryng in a canine elbow osteoarthritis study currently underway. Deployed several new highly experience business development managers for coverage across several U.S. states and regions to provided localized coverage and support for veterinarian clinics and distributors. Added Vedco, Inc. and Clipper Distributing, LLC to company's nationwide distributors network, who in turn supply veterinary products to some of the nation's largest veterinary product distributors in the U.S., including MWI, Covetrus, Patterson, Midwest Supply, Penn Supply and others. They have quickly ramped up and collectively contributing more than $483,000 in sales during the last four months of the fiscal year. Exhibited and spoke at seven major veterinary conferences as well as at several smaller industry events during the fiscal year, demonstrating the research-backed benefits of Spryng ® to veterinarians, including leading sports medicine and rehabilitation experts in the veterinary industry. The events have helped to drive greater adoption of Spryng ® by expanding the awareness among key decision-makers of its effectiveness and benefits in the treatment of osteoarthritis in animals. to veterinarians, including leading sports medicine and rehabilitation experts in the veterinary industry. The events have helped to drive greater adoption of Spryng by expanding the awareness among key decision-makers of its effectiveness and benefits in the treatment of osteoarthritis in animals. Significantly bolstered the company's executive leadership with the appointment of board member, Mike Eldred, as the company's commercialization and operations advisor. He has brought to the position more than 30 years of executive experience in animal health and the veterinary industry, and has been responsible for advancing product development and driving sales growth. He previously built Dechra Pharmaceutical's North American subsidiary into one of the fastest growing companies in the industry, with more than 250 employees and annual revenue exceeding $450 million. Subsequent Events Signed definitive distribution agreement with Eq Especialidades to inventory, market and promote Spryng ® throughout Mexico, representing the company's first entrance into the international market. throughout Mexico, representing the company's first entrance into the international market. Established a strategic partnership with PiezoBioMembrane, a pioneer in biodegradable piezoelectric materials intended for implantable applications, to advance research and development of revolutionary functional biomaterials that promote regeneration and/or remodeling of damaged or injured tissue and bone in animals and humans. Closed the remaining $4.4 million purchase option as part of a private placement offering initiated in March 2025 totaling $5 million in equity financing in exchange for five million shares of the company's Series B convertible preferred stock at $1.00 per share, with a preferred share to a common share on a one-for-one basis. Management Commentary 'Fiscal year ending March 31, 2025 was a strong and very productive year for PetVivo, as we continued to expand the use of our lead animal osteoarthritis medical device, Spryng® with OsteoCushion® Technology, as well as our new, innovative product, PrecisePRP®, and this resulting in another year of record sales,' commented PetVivo CEO, John Lai. 'We also greatly strengthened our product platform with the addition of innovative technologies from new major partnerships that we formed during the year—technologies involving both diagnostics and new medical treatments that we expect to be transformative for both our platform and the veterinarians we serve. We anticipate these to become strong future growth drivers. 'Since the market introduction of Spryng® the fall of 2021, it has now been used by more than 1,000 veterinary clinics across all 50 states. Now with the recent addition of or first international distributor in Mexico, we can count on several new clinics in that country using Spryng®. 'The North American expansion of our distribution network also helped drive the double-digit revenues growth for the year, with our nationwide distributor network now contributing 85% of our total revenues. This growth demonstrates how our distributors have become strong force-multipliers for our in-house sales force and regional managers. 'Our strong topline results also reflect the success of our transition from addressing primarily the equine market to expanding into the much larger and faster-growing companion animal market. Our increased emphasis on this market required a full realignment of our sales force during the year. We deployed several new highly experienced territory managers nationwide, as well as added new leadership and professional sales representatives to support them. 'Our new internal sales reps and technical service veterinarians are supporting our sales and marketing teams as they further develop relationships with the nation's leading veterinary clinics and distributors. These moves resulted in an increased portion of our overall revenues generated from this companion animal market, while maintaining very a favorable overall high gross margin of 87.8%. 'Our sales and marketing programs were also greatly strengthened with April Boyce becoming our new vice president of sales and marketing. In this position, she has been applying her more than 25 years of experience in marketing, sales, strategic partnerships, and global product licensing, including executive positions at Procter & Gamble and Clorox. Her efforts have been truly transformative for our company as we've worked to expand further into the companion animal marketplace. 'We also greatly enhanced our distribution and corporate accounts team leadership with the appointment of Bryan Monninger as vice president of distributor relations and corporate accounts. He brought to us more than 20 years of success in sales and marketing while serving in senior executive positions at Hill's Pet Nutrition, Novus International, and Lintbells, as well as at the Fortune 500 companies of Colgate-Palmolive, ConAgra and Hormel Foods. 'Also, during the year, we strengthened our board and leadership team with the appointment of Mike Eldred to our board of directors, and then with his appointment as our commercialization and operations advisor. In this new position, he has been championing our refocused operations and commercialization efforts. 'Mike has brought to us more than 30 years of executive experience and accomplishment in animal health and the veterinary industry. Most notably, he built Dechra Pharmaceutical's North American subsidiary into one of the fastest growing companies in the industry, with more than 250 employees and annual revenue exceeding $450 million. His experience and strong record of achievement in pharmaceutical and animal health provides us a tremendously valuable resource for achieving our business goals. 'Investors have also taken notice of our success and strengthened future growth prospects, as evidenced by our successful offering of a $5 million Series B Convertible Preferred Stock which we announced as fully funded and closed last week. The proceeds have been earmarked to support the further commercialization and market penetration of our lead animal health products. 'Our overall strategy to drive the greater adoption of Spryng® has been to expand the awareness of its effectiveness and benefits among key decision-makers, and to do this at an increasingly greater scale. Toward this end, during the year we exhibited at several major veterinary conferences across the country, seven in total, as well participated in several smaller industry events. These events have presented valuable opportunities to demonstrate the advantages of Spryng® to key decision makers and show firsthand the beneficial results from administering Spryng® to horses and companion animals. 'From these events we have also gained a better understanding of our market and the types of veterinarians we should be targeting. This includes vets who specialize in surgery, sport medicine, rehabilitation and/or pain management. Such specialties in the veterinary medical field have increased in recent years, primarily due to the many advancements made in veterinary science, the growing population of pet owners and their desire for specialized care. 'This trend is also being driven by the increasing adoption of pet insurance that helps make advanced treatments more accessible and affordable. All of these trends bode well for the greater adoption of Spryng® and PrecisePRP as well as the other new product offerings we've added to our platform. 'We have continued to accumulate impressive data from a new canine elbow study being conducted by Orthobiologic Innovations, a leader in R&D for regenerative and sports medicine. We expect it to be completed before the end of the calendar year. Such clinical studies play a crucial role in our distribution strategy because large national and international distributors typically desire university or independently conducted research before they add a new product to their catalog. 'To further extend our market reach with greater efficacy, in the latter part of the year we added Vedco, Inc. and Clipper Distributing, LLC to our nationwide distributors network. Both have quickly ramped up and collectively contributed more than $483,000 in sales in just the final four months of the fiscal year. 'We also expanded our technology platform with the signing of an exclusive licensing and supply agreement with VetStem, Inc. that grants us the right to commercialize their revolutionary PrecisePRP, a allogeneic platelet rich plasma product for horses and dogs. This is a first-in-class off-the-shelf platelet-rich plasma product designed for use by veterinarians for elite equine athletes. 'We recently announced a new strategic collaboration with Commonwealth Markets, Inc., the syndicated ownership group behind the 2023 Kentucky Derby winner. Commonwealth will integrate Spryng® and Precise PRP into the care protocols of its top-tier thoroughbred stable. They will be used as a preventative measure and as a treatment solution to promote joint health, extend performance longevity, and support recovery in high-impact training and racing environments. 'We also recently established a strategic partnership with PiezoBioMembrane, Inc., a pioneer in biodegradable piezoelectric materials intended for implantable applications. Together we plan to advance the research and development of revolutionary functional biomaterials which promote regeneration and remodeling damaged or injured tissue and bones. 'In March of this year, we entered a groundbreaking and transformative strategic alliance with Digital Landia, Inc., a pioneer in Agentic AI solutions. This collaboration focuses on Pet AI, Digital Landia's revolutionary technology that deciphers animal behavior and communication at an amazing 97% accuracy through the real-time analysis of vocalizations, body language, and physiological signals captured via a Smartphone camera. 'This AI technology represents a paradigm shift in how we understand our pets. By aligning our clinically proven therapies with this technology, we have uniquely positioned PetVivo at the intersection of AI innovation and veterinary care. 'We anticipate Pet AI will rival mainstream AI applications in adoption rates, creating unparalleled visibility for our brands, including Spryng® and PrecisePRP. The technology is currently being integrated with our veterinary products as a first-of-kind global pet care ecosystem, with initial beta testing now underway. We're looking forward to announcing some amazing results. 'Altogether, the cross pollination of these technologies is creating an exciting new future for PetVivo, one that is transformative for not only us but also for the veterinarians and the precious patients they serve. 'As the result of the many inroads we have made at conferences over the past year, combined with our expanded sales force and distributor network and our more efficient operational structure, we expect to see continued strong sales momentum and market penetration in fiscal 2026. 'In fact, we have never been in a greater position to accelerate our growth and expand into our high growth markets over the coming year and beyond. The U.S. animal health market is projected to double to $11.3 billion by 2030. Such massive growth is rare for such an already large industry, and it provides us tremendous tailwinds. 'As we continue to grow and expand, we will remain committed to advancing the best in pet health solutions and ensuring that our products reach more veterinary professionals and pet owners. For fiscal 2026, we look forward to building upon the many advancements we made over the last year and driving greater value for our stakeholders.' Fiscal 2026 Outlook For the full fiscal year ending March 31, 2026, the company anticipates another year of record growth and improving bottom line as it continues to expand the use of its Spryng® with OsteoCushion® Technology as well as other new products offered by its expanded medical therapeutics platform. Conference Call PetVivo management will host a conference call later today to discuss these results, which will include a question-and-answer period. Date: Monday, June 30, 2025Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific time)Toll-free dial-in number: +1 (253) 205-0468Conference ID: 83424004566Passcode: 352845 Webcast (live & replay): click here A replay of the webcast will be available through the same link following the conference call. The conference call webcast is also available via a link in the Investors section of the company's website at About PetVivo Holdings PetVivo Holdings Inc. (OTCQB: PETV; OTCPINK: PETVW), and its wholly-owned subsidiary PetVivo Animal Health, Inc., is an emerging biomedical device company focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices which enter the market much earlier than more stringently regulated pharmaceuticals and biologics. PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of 12 patents protect the company's biomaterials, products, production processes and methods of use. The company's lead products SPRYN® with OsteoCushion™ technology, is a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses. It also offers PrecisePRP, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians. Both are currently available for commercial sale. To learn more, visit or Disclosure Information PetVivo uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the company's Investor Relations website, in addition to following the company's press releases, SEC filings, public conference calls, presentations and webcasts. Forward-Looking Commercial Statements The foregoing information regarding PetVivo Holdings, Inc. (the 'Company') may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company's proposed development and commercial timelines, and can be identified by the use of words such as 'may,' 'will,' 'expect,' 'project,' 'estimate,' 'anticipate,' 'plan,' 'believe,' 'potential,' 'should,' 'continue' or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company's business are described in detail in the Company's Annual Report on Form 10-K for the year ended March 31, 2025 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise. Company ContactJohn Lai, CEOPetVivo Holdings, Contact Tel (952) 405-6216 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
